Serum alanine aminotransferase (ALT) increase is a well-known phenomenon during interferon treatment for chronic hepatitis B. However, little is known about these increases during nucleoside/ nucleotide treatment and the effects on long-term clinical outcomes.
Methods
A total of 170 treatment-naive hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients were treated with a nucleoside/nucleotide analogue for at least 2 years and followed up for 1 more year post-treatment. Clinical characteristics were detected and analysed at baseline and at every 3-month interval.
Results
Two patterns of ALT increase, virus- and host-induced, were detected. Virus-induced increases were characterized by a rapid increase in serum ALT and HBV DNA typically after 2 years of treatment, and were more common than host-induced ALT increases (15.9% versus 6.5%; P<0.05) with a median ALT increase of 5.7fold the upper limit of normal (ULN). Host-induced ALT increases were characterized by moderately increased ALT (median 2.5-fold ULN) with a slow decrease in HBV DNA that occurred mainly in the first year of treatment (63.6%). Most importantly, host-induced increases were associated with favourable long-term treatment outcomes in HBV DNA undetectable rate (82% versus 0%), HBeAg seroconversion (82% versus 7%) and histological improvement. Moreover, interferon-γ-expressing T-helper cells were increased in patients with host-induced ALT increases.
Conclusions
Two patterns of ALT increases may occur during nucleoside/nucleotide analogue treatment. Host induced ALT increases, accompanied by decreased HBV DNA, lead to better long-term clinical outcomes.
References
1.
PerrilloR.P.Acute fares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology2001; 120: 1009–1022.
2.
YuenM.F., YuanH.J., HuiC.K.A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut2003; 52: 416–419.
3.
TsaiS.L., ChenP.J., LaiM.Y.Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest1992; 89: 87–96.
4.
NairS., PerrilloR P.Serum alanine aminotransferase fares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?Hepatology2001; 34: 1021–1026.
5.
FlinkH.J., SprengersD., HansenB.E.Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon alpha-2b therapy. Gut2005; 54: 1604–1609.
6.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet2005; 365: 123–129.
7.
TangT.J., KwekkeboomJ., LamanJ.D.The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection. J Viral Hepat2003; 10: 159–167.
8.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med2005; 352: 2682–2695.
9.
YouH., MaH., LiuT.Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles. J Viral Hepat2009; 16: 876–882.
10.
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. [The guidelines of prevention and treatment for chronic hepatitis B.]Zhonghua Gan Zang Bing Za Zhi.2005; 13: 881–891. Chinese.
11.
LokA.S., McMahonB.J. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology2004; 39: 857–861.
12.
KumarM., ChauhanR., GuptaN.Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology2009; 136: 1272–1280.
MassettoB., MenzaghiB., GiambelliC.The good and evil of fare: fares in hepatitis B virus chronic hepatitis. Eur J Gastroenterol Hepatol2007; 19: 821–823.
15.
ter BorgM.J., HansenB.E., BigotG.ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol2008; 42: 160–164.
16.
ter BorgM.J., van ZonneveldM., ZeuzemS.Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology2006; 44: 721–727.
17.
KondoY., AsabeS., KobayashiK.Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol2004; 74: 425–433.
18.
SarinS.K., SandhuB.S., SharmaB.C.Beneficial effects of ‘lamivudine pulse’ therapy in HBeAg-positive patients with normal ALT. J Viral Hepat2004; 11: 552–558.
19.
EvansA., RivaA., CooksleyH.Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology2008; 48: 759–769.
